Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Gilead Sciences, Inc., v. Teva Pharmaceuticals USA, Inc. et al
Case Number:
1:10-cv-01796
Court:
Nature of Suit:
Judge:
Firms
- Fitzpatrick Cella
- Giaccio LLC
- Goodwin Procter
- Hunton Andrews
- Kelley Drye
- Kenyon & Kenyon
- Mayer Brown
- O'Melveny & Myers
- Orrick Herrington
- Venable LLP
- Winston & Strawn
Companies
Sectors & Industries:
-
February 20, 2013
Teva Settles Gilead's HIV Drug Patent Suit As Trial Looms
Teva Pharmaceuticals USA Inc. has agreed to a settlement with Gilead Sciences Inc. to end a patent infringement dispute over its planned generic version of antiviral treatment Viread, heading off a trial that was set to begin Wednesday in New York federal court, Gilead said Tuesday.
-
February 07, 2013
Teva Can't Swap Out Expert In HIV Drug Patent Trial
A New York federal judge on Wednesday shot down Teva Pharmaceuticals USA Inc.'s bid to switch out its expert witness for its upcoming trial versus Gilead Sciences Inc. over patents for HIV drugs, finding substituting an expert at this stage would be unfair to Gilead.